Trial Details
ACTIVE_NOT_RECRUITINGBasic Information
| Clinical ID | c1296 |
|---|---|
| Identifier | NCT05242471 |
| Trial Title | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOLOGICAL: JNJ-78934804|DRUG: Placebo |
Participant Information
| Sponsor | Janssen Research & Development, LLC |
|---|---|
| City | Birmingham |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2022-07-22 |
|---|---|
| Primary Completion Date | 2025-05-23 |
| Completion Date | 2029-11-05 |